Tara Jarboe

Mrs. Tara Jarboe


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KKKaci Kopec
Kaci Kopec
DQDanielle Quaranto
Danielle Quaranto
NDNicole R. DeSouza
Nicole R. DeSouza
TJTara Jarboe
Tara Jarboe
HIHumayun Kamal Islam
Humayun Kamal Islam
Raj K. TiwariRaj K. Tiwari
Raj K. Tiwari
The HOX gene family encodes for regulatory transcription factors that play a crucial role in embryogenesis and differentiation of adult cells. This highly conserved family of genes consists of thirty-nine genes in humans that are located in four clusters, A–D, on different chromosomes. While early studies on the HOX gene family have been focused on embryonic development and its related disorders, research has shifted to examine aberrant expression of HOX genes and the subsequent implication in cancer prediction and progression. Due to their role of encoding master regulatory transcription factors, the abnormal expression of HOX genes has been shown to affect all stages of tumorigenesis and metastasis. This review highlights the novel role of the HOX family’s clinical relevance as both prognostic and diagnostic biomarkers in hematological and solid tumors.

Verified
Journal Article
Open access
PDF file
NDNicole R. DeSouza
Nicole R. DeSouza
DQDanielle Quaranto
Danielle Quaranto
MCMichelle Carnazza
Michelle Carnazza
TJTara Jarboe
Tara Jarboe
Raj K. TiwariRaj K. Tiwari
Raj K. Tiwari
JGJan Geliebter
Jan Geliebter
RNA biology has gained extensive recognition in the last two decades due to the identification of novel transcriptomic elements and molecular functions. Cancer arises, in part, due to the accumulation of mutations that greatly contribute to genomic instability. However, the identification of differential gene expression patterns of wild-type loci has exceeded the boundaries of mutational study and has significantly contributed to the identification of molecular mechanisms that drive carcinogenic transformation. Non-coding RNA molecules have provided a novel avenue of exploration, providing additional routes for evaluating genomic and epigenomic regulation. Of particular focus, long non-coding RNA molecule expression has been demonstrated to govern and direct cellular activity, thus evidencing a correlation between aberrant long non-coding RNA expression and the pathological transformation of cells. lncRNA classification, structure, function, and therapeutic utilization have expanded cancer studies and molecular targeting, and understanding the lncRNA interactome aids in defining the unique transcriptomic signatures of cancer cell phenotypes.

27 April 2024 in Biology
Verified
Journal Article
Open access
PDF file
NDNicole R. DeSouza
Nicole R. DeSouza
TJTara Jarboe
Tara Jarboe
MCMichelle Carnazza
Michelle Carnazza
DQDanielle Quaranto
Danielle Quaranto
HIHumayun K Islam
Humayun K Islam
JGJan Geliebter
Jan Geliebter
Thyroid Cancer (TC) is the most common endocrine malignancy, with increasing incidence globally. Papillary thyroid cancer (PTC), a differentiated form of TC, accounts for approximately 90% of TC and occurs predominantly in women of childbearing age. Although responsive to current treatments, recurrence of PTC by middle age is common and is much more refractive to treatment. Undifferentiated TC, particularly anaplastic thyroid cancer (ATC), is the most aggressive TC subtype, characterized by it being resistant and unresponsive to all therapeutic and surgical interventions. Further, ATC is one of the most aggressive and lethal malignancies across all cancer types. Despite the differences in therapeutic needs in differentiated vs. undifferentiated TC subtypes, there is a critical unmet need for the identification of molecular biomarkers that can aid in early diagnosis, prognosis, and actionable therapeutic targets for intervention. Advances in the field of cancer genomics have enabled for the elucidation of differential gene expression patterns between tumors and healthy tissue. A novel category of molecules, known as non-coding RNAs, can themselves be differentially expressed, and extensively contribute to the up- and downregulation of protein coding genes, serving as master orchestrators of regulated and dysregulated gene expression patterns. These non-coding RNAs have been identified for their roles in driving carcinogenic patterns at various stages of tumor development and have become attractive targets for study. The identification of specific genes that are differentially expressed can give insight into mechanisms that drive carcinogenic patterns, filling the gaps of deciphering molecular and cellular processes that modulate TC subtypes, outside of well-known driver mutations.

30 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NDNicole R. DeSouza
Nicole R. DeSouza
MCMichelle Carnazza
Michelle Carnazza
TJTara Jarboe
Tara Jarboe
DQDanielle Quaranto
Danielle Quaranto
KKKaci Kopec
Kaci Kopec
Raj K. TiwariRaj K. Tiwari
Raj K. Tiwari
Background: Long non-coding RNAs (lncRNAs) are regulatory molecules that have multifaceted impacts on the carcinogenic molecular landscape—with pathologic consequences when aberrantly expressed. Anaplastic thyroid cancer (ATC) is a rapidly progressing and highly lethal malignancy, with mortality rates approaching 100%. The molecular/transcriptomic signature of ATC has significant gaps in understanding; thus, a comprehensive study of ATC non-coding RNA transcript regulation is necessary. Results: The lncRNA Double Homeobox A Pseudogene 10 (DUXAP10) was identified in patient genomic datasets as a highly upregulated transcript in ATC vs. normal thyroid tissue. DUXAP10 expression was transcriptionally repressed with CRISPR-interference (CRISPRi), and data supports an extensive role of DUXAP10 in several cancer-promoting phenotypes in ATC, both in vitro and in vivo. Our two DUXAP10-CRISPRi cell lines significantly reduced the rapid growth and metastatic behaviors characteristic of ATC, affecting proliferation, viability, clonogenicity, apoptosis, invasion, migration, tumorigenesis, and metastasis. Conclusion: Thus, DUXAP10 is a proposed prognostic marker and therapeutic target for ATC disease propagation and progression.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
KKKaci Kopec
Kaci Kopec
TJTara Jarboe
Tara Jarboe
MSMordechai Sternman
Mordechai Sternman
NDNicole R. DeSouza
Nicole R. DeSouza
SSSarnath Singh
Sarnath Singh
XLXiu-Min Li
Xiu-Min Li
Anaplastic thyroid cancer (ATC) is an undifferentiated thyroid cancer. A hallmark of ATC is increased inflammatory cytokine expression and inflammatory cell infiltration in the tumor microenvironment that is responsible for its aggressive nature. In contrast, papillary thyroid cancer (PTC) is well-differentiated and subsequently significantly less aggressive and more responsive to available therapies. The metabolic differences between ATC and PTC that correlate with differentiation status, and hence metastatic propensity, are poorly understood. Owing to its lack of differentiation, ATC is radioiodine therapy resistant, whereas differentiated thyroid cancers are susceptible. AMPK in the thyroid gland is responsible for glucose and iodine uptake. The AMPK pathway is a potential target for modulation due to the higher glucose uptake and metabolism associated with treatment resistance seen in ATC. Berberine, a naturally occurring plant alkaloid, regulates glycometabolism and lipid metabolism, improves energy expenditure, and reduces body weight. Exploration of a possible connection between the metabolic regulation displayed by BBR and AMPKα expression was warranted. Increased AMPKα signaling, observed through increased AMPKα phosphorylation, has an anti-tumor effect. When comparing PTC (TPC1) and ATC (T238) cell lines there was a 4.75- and 2.34-fold change, respectively, in phosphorylation of AMPKα upon BBR treatment. This demonstrates that BBR increases metabolic regulation in thyroid cancer cell lines, importantly, even when poorly differentiated. Further analysis of the correlation between differentiation status and metabolic characteristics between ATC and PTC was investigated using RNASeq. Differential gene expression was conducted to compare ATC and PTC using human thyroid cancer cell lines T238 and K1, respectively. These thyroid cancer cell lines were treated with 100 μM BBR or the same concentration of DMSO as a vehicle control for 24 hours. RNA was isolated from T238 and K1 cells and RNASeq was conducted by GeneWiz. This differential gene expression will help identify specific genes that are regulating metabolic patterns and is currently ongoing. Berberine (BBR) is a natural compound used widely in Traditional Chinese Medicine for its many pharmacological properties including anti-inflammatory, metabolic, antioxidant, and anti-cancer. BBR may be able to mitigate the metabolic pattern of ATC to potentially affect differentiation status as an intervening product. Intervention of the differentiation status of ATC will impact its progression, specifically metastasis. Therefore, identifying gene patterns that correlate with differentiation status will identify novel intervention targets for BBR. Citation Format: Kaci Kopec, Tara Jarboe, Mordechai Sternman, Nicole R. DeSouza, Sarnath Singh, Augustine Moscatello, Jan Geliebter, Raj K. Tiwari, Xiu-Min Li. Metabolic modulation of anaplastic thyroid cancer by Berberine: A targeted intervention [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1410.